Tirzepatide · 3 min read
Tirzepatide activates two incretin receptors at once. What GIP adds to GLP-1 agonism, why the dual mechanism produces more weight loss, and what it means for side effects.
Tirzepatide activates two incretin receptors at once. What GIP adds to GLP-1 agonism, why the dual mechanism produces more weight loss, and what it means for side effects.
Tirzepatide is a single synthetic peptide, 39 amino acids engineered on a GIP backbone with a C20 fatty-diacid moiety, that activates two incretin receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. That dual activity — sometimes called a "twincretin" mechanism — is the pharmacological reason it outperforms pure GLP-1 agonists on weight endpoints.
GLP-1 is an incretin hormone released from intestinal L-cells after eating. Activating its receptor does four relevant things: it amplifies glucose-dependent insulin secretion (insulin rises when glucose is high, not when it is normal — which is why hypoglycemia is rare without other diabetes drugs); it suppresses inappropriate glucagon release; it slows gastric emptying, extending fullness after meals; and it acts on hypothalamic and hindbrain appetite circuits to reduce hunger and food reward. Semaglutide does all of this. So does tirzepatide.
GIP was long dismissed as a weight-loss target — it is secreted from K-cells and was historically associated with fat storage. The modern picture is different: in combination with GLP-1 agonism, GIP receptor activity appears to add central appetite effects through distinct hypothalamic populations, improve adipose tissue insulin sensitivity and lipid buffering, and — notably — attenuate the nausea signaling that limits GLP-1 dosing. That last point matters clinically: it is one proposed reason tirzepatide reaches high, effective exposures with GI tolerability comparable to semaglutide despite greater weight loss.
The fatty-diacid chain binds albumin, protecting the peptide from degradation and giving tirzepatide a half-life of about five days — hence once-weekly injection and the ability to shift a dose day by a couple of days without losing steady-state coverage. Steady state arrives after roughly four weeks at a given dose, which is also why the titration ladder moves in four-week steps.
Dual agonism predicts larger weight loss than GLP-1 alone, and the trials delivered: 15.0% to 20.9% average reductions across doses in SURMOUNT-1 versus placebo's 3.1%, and 20.2% versus semaglutide's 13.7% in the head-to-head SURMOUNT-5. It also predicts strong glycemic effects — tirzepatide produced the largest A1C reductions ever seen in the SURPASS diabetes program — and metabolic improvements in lipids, blood pressure, and liver fat that track the weight loss. The mechanism is also why the drug stops working when you stop taking it: it replaces a hormonal signal rather than resetting the system, which is the subject of what happens when you stop a GLP-1.
Partly. Tirzepatide activates the GLP-1 receptor and the GIP receptor — it is a dual incretin agonist, which is why it is often grouped with GLP-1 drugs but outperforms pure GLP-1 agonists on weight endpoints.
GIP receptor activity appears to attenuate the nausea signaling associated with GLP-1 agonism, allowing higher effective exposures with comparable GI tolerability. Nausea is still the most common side effect, concentrated during dose increases.
The half-life is about five days, so it takes roughly four to five weeks to clear after the last dose — and about four weeks at any dose to reach steady state.